share_log

Canaccord Genuity Maintains Buy on Cardiol Therapeutics, Raises Price Target to $6

Canaccord Genuity Maintains Buy on Cardiol Therapeutics, Raises Price Target to $6

Canaccord Genuity 維持對 Cardiol Therapeutics 的買入,將目標價上調
Benzinga ·  2023/05/19 07:55

Canaccord Genuity analyst Edward Nash maintains Cardiol Therapeutics (NASDAQ:CRDL) with a Buy and raises the price target from $5 to $6.

Canaccord Genuity分析師愛德華·納什維持Cardiol Therapeutics(納斯達克股票代碼:CRDL)的買入,並將目標股價從5美元上調至6美元。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論